Cidara Therapeutics Net Income 2014-2022 | CDTX

Cidara Therapeutics net income from 2014 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Cidara Therapeutics Annual Net Income
(Millions of US $)
2021 $-42
2020 $-75
2019 $-41
2018 $-69
2017 $-56
2016 $-48
2015 $-32
2014 $-12
2013 $-1
Cidara Therapeutics Quarterly Net Income
(Millions of US $)
2022-03-31 $-18
2021-12-31 $-15
2021-09-30 $-18
2021-06-30 $9
2021-03-31 $-18
2020-12-31 $-22
2020-09-30 $-18
2020-06-30 $-18
2020-03-31 $-17
2019-12-31 $-14
2019-09-30 $3
2019-06-30 $-14
2019-03-31 $-17
2018-12-31 $-12
2018-09-30 $-14
2018-06-30 $-27
2018-03-31 $-17
2017-12-31 $-13
2017-09-30 $-12
2017-06-30 $-17
2017-03-31 $-13
2016-12-31 $-14
2016-09-30 $-12
2016-06-30 $-12
2016-03-31 $-10
2015-12-31 $-10
2015-09-30 $-9
2015-06-30 $-6
2015-03-31 $-7
2014-12-31 $-5
2014-09-30 $-3
2014-06-30 $-3
2014-03-31 $-1
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.030B $0.050B
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00